跳至主要内容
临床试验/CTRI/2014/09/005041
CTRI/2014/09/005041招募中4 期

Comparative study evaluating Quality Of Life of chemotherapy versus Oral TKI in third line and beyond Setting for advanced non-small cell lung cancer

Tata Memorial Hospital0 个研究点目标入组 200 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
招募中
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Pms

入排标准

入选标准

  • Inclusion criteria :
  • TKI-naive patients with documented stage IIIB ( treated with palliative intent) or stage IV NSCLC who have progressed on first and second line chemotherapy regimens
  • .2. ECOG Performance status (PS) from 0 to 2
  • 3. Age >= 18yrs
  • 4. Adequate bone marrow tests (absolute neutrophil count >1500/lL, hemoglobin > 8 g/dL, and platelet count >100,000/lL), renal function tests (creatinine <2 mg/dL), and liver function tests (total bilirubin <1.5 times the institutional upper limit of normal [ULN], aspartate aminotransferase and alanine aminotransferase levels <2 times the institutional ULN);
  • 5. Life expectancy >= 3 months
  • 6. Clinically stable brain metastases if any

排除标准

  • 1.Prior therapy with TKI
  • 2.Patients with EGFR mutation
  • 3. A second primary tumor
  • 4. Uncontrolled infection
  • 5.Uncontrolled co-morbidities

研究者

相似试验